2023
DOI: 10.1016/j.fct.2022.113559
|View full text |Cite
|
Sign up to set email alerts
|

New approach methodologies: A quantitative in vitro to in vivo extrapolation case study with PFASs

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
5
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5
1

Relationship

2
4

Authors

Journals

citations
Cited by 9 publications
(5 citation statements)
references
References 80 publications
(163 reference statements)
0
5
0
Order By: Relevance
“…To obtain in vivo relative potencies based on in vitro toxicity data, information on toxicokinetics should be included in the assessment. In that regard, we have been working on the quantitative in vitro to in vivo extrapolation (QIVIVE) of the toxicity data of PFOA, PFNA, PFHxS, and PFOS, translating cell-associated PFAS levels to oral equivalent doses using physiologically based kinetic (PBK) modeling, providing information that will be of use in the assessment of relative potencies of PFASs in humans (Fragki et al 2023 ).…”
Section: Discussionmentioning
confidence: 99%
“…To obtain in vivo relative potencies based on in vitro toxicity data, information on toxicokinetics should be included in the assessment. In that regard, we have been working on the quantitative in vitro to in vivo extrapolation (QIVIVE) of the toxicity data of PFOA, PFNA, PFHxS, and PFOS, translating cell-associated PFAS levels to oral equivalent doses using physiologically based kinetic (PBK) modeling, providing information that will be of use in the assessment of relative potencies of PFASs in humans (Fragki et al 2023 ).…”
Section: Discussionmentioning
confidence: 99%
“… In the model for PFNA and PFHxS the tissue/blood partition coefficients were adjusted for liver and kidney according to Fragki et al [26] . In the Table 2 , Table 3 the input parameters for PFNA and PFHxS are reported as taken from Fragki et al [26] . …”
Section: Methodsmentioning
confidence: 99%
“…In the case of PFNA and PFHxS, tissue-blood partition coefficients were used for PFOA and PFOS, respectively, with the exception of liver and kidney, were data used were derived from rodent studies [approach followed as by 26]. Again here, transporter maximum capacity for renal tubular reabsorption is fitted in order to achieve the desired half-life in humans [26] . However, due to the absence of suitable human biomonitoring data, the PFNA and PFHxS models could not be verified directly on such data [26] .…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…To facilitate the quantitative in vitro -to- in vivo extrapolation (QIVIVE) for PFAS, the concentration–response curves from in vitro bioassays should be derived with free concentrations of PFAS to obtain freely dissolved effect concentrations, which can be compared to the actual PFAS levels that human are exposed to (i.e., freely dissolved concentrations in human plasma). Fetal bovine serum (FBS) is typically used as the nutrient supply in an in vitro cell-based bioassay, while fish and mice are common in vivo animal models. To make the results from the different in vitro and in vivo models comparable and to allow extrapolation to humans, plasma binding of PFAS among different species needs to be known, but it has not been assessed for PFAS systematically so far.…”
Section: Introductionmentioning
confidence: 99%